Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma

Background: Tyrosine kinase inhibitors (TKIs) prolong progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC), some of which may achieve long-term responses. Herein, we report clinical and pathological characteristics of patients who achieved long-term responses durin...

Descripción completa

Detalles Bibliográficos
Autores principales: Catalano, Martina, De Giorgi, Ugo, Maruzzo, Marco, Bimbatti, Davide, Buti, Sebastiano, Mazzaschi, Giulia, Procopio, Giuseppe, Santoni, Matteo, Galli, Luca, Conca, Raffaele, Doni, Laura, Antonuzzo, Lorenzo, Roviello, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599295/
https://www.ncbi.nlm.nih.gov/pubmed/36289706
http://dx.doi.org/10.3390/biomedicines10102444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599295/
https://www.ncbi.nlm.nih.gov/pubmed/36289706
http://dx.doi.org/10.3390/biomedicines10102444

Ejemplares similares